AusperBio Reaches Key Milestone with Dosing Completion and Study Unblinding in Ongoing AHB-137 Phase IIb Trial

Posted on by

SAN FRANCISCO, Feb. 11, 2025 /PRNewswire/ — AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced recent progress in the ongoing clinical development of its lead candidate AHB-137, an antisense…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.